NO20062965L - NK-1-Reseptorantagonister - Google Patents
NK-1-ReseptorantagonisterInfo
- Publication number
- NO20062965L NO20062965L NO20062965A NO20062965A NO20062965L NO 20062965 L NO20062965 L NO 20062965L NO 20062965 A NO20062965 A NO 20062965A NO 20062965 A NO20062965 A NO 20062965A NO 20062965 L NO20062965 L NO 20062965L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonist
- butyl
- anesthesia
- tert
- isopropyl
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54069704P | 2004-01-30 | 2004-01-30 | |
| PCT/IB2005/000010 WO2005082366A1 (en) | 2004-01-30 | 2005-01-06 | Nk-1 receptor antagonists anesthesia recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062965L true NO20062965L (no) | 2006-07-21 |
Family
ID=34910695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062965A NO20062965L (no) | 2004-01-30 | 2006-06-26 | NK-1-Reseptorantagonister |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070155782A1 (https=) |
| EP (1) | EP1713479A1 (https=) |
| JP (1) | JP2007519701A (https=) |
| KR (1) | KR100880391B1 (https=) |
| CN (1) | CN1913893A (https=) |
| AU (1) | AU2005216706B2 (https=) |
| BR (1) | BRPI0507325A (https=) |
| CA (1) | CA2554823A1 (https=) |
| IL (1) | IL176830A0 (https=) |
| MX (1) | MXPA06007964A (https=) |
| NO (1) | NO20062965L (https=) |
| RU (1) | RU2337685C2 (https=) |
| WO (1) | WO2005082366A1 (https=) |
| ZA (1) | ZA200605149B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1713504T (lt) | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| RU2489765C1 (ru) * | 2012-01-10 | 2013-08-10 | Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") | Способ изготовления газонаполненного разрядника |
| CN114984223B (zh) * | 2022-05-31 | 2023-06-20 | 中国人民解放军陆军军医大学第二附属医院 | 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用 |
| AT527172A1 (de) * | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US540897A (en) | 1895-06-11 | Harold f | ||
| US540644A (en) | 1895-06-11 | del yalle | ||
| AU657552B2 (en) | 1991-05-31 | 1995-03-16 | Pfizer Inc. | Quinuclidine as substance P antagonists |
| US5393762A (en) | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6255320B1 (en) | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| PL367944A1 (en) | 2001-07-20 | 2005-03-07 | Pfizer Products Inc. | Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
-
2005
- 2005-01-06 CA CA002554823A patent/CA2554823A1/en not_active Abandoned
- 2005-01-06 CN CNA2005800036680A patent/CN1913893A/zh active Pending
- 2005-01-06 MX MXPA06007964A patent/MXPA06007964A/es not_active Application Discontinuation
- 2005-01-06 US US10/587,590 patent/US20070155782A1/en not_active Abandoned
- 2005-01-06 KR KR1020067015267A patent/KR100880391B1/ko not_active Expired - Fee Related
- 2005-01-06 RU RU2006126828/15A patent/RU2337685C2/ru not_active IP Right Cessation
- 2005-01-06 AU AU2005216706A patent/AU2005216706B2/en not_active Ceased
- 2005-01-06 JP JP2006550323A patent/JP2007519701A/ja not_active Withdrawn
- 2005-01-06 WO PCT/IB2005/000010 patent/WO2005082366A1/en not_active Ceased
- 2005-01-06 BR BRPI0507325-1A patent/BRPI0507325A/pt not_active IP Right Cessation
- 2005-01-06 EP EP05702181A patent/EP1713479A1/en not_active Withdrawn
-
2006
- 2006-06-22 ZA ZA200605149A patent/ZA200605149B/en unknown
- 2006-06-26 NO NO20062965A patent/NO20062965L/no not_active Application Discontinuation
- 2006-07-13 IL IL176830A patent/IL176830A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070155782A1 (en) | 2007-07-05 |
| AU2005216706B2 (en) | 2007-11-29 |
| AU2005216706A1 (en) | 2005-09-09 |
| MXPA06007964A (es) | 2007-01-26 |
| BRPI0507325A (pt) | 2007-07-03 |
| WO2005082366A1 (en) | 2005-09-09 |
| KR20060127934A (ko) | 2006-12-13 |
| CN1913893A (zh) | 2007-02-14 |
| RU2006126828A (ru) | 2008-03-10 |
| CA2554823A1 (en) | 2005-09-09 |
| WO2005082366A8 (en) | 2005-12-15 |
| IL176830A0 (en) | 2006-10-31 |
| JP2007519701A (ja) | 2007-07-19 |
| EP1713479A1 (en) | 2006-10-25 |
| KR100880391B1 (ko) | 2009-01-30 |
| RU2337685C2 (ru) | 2008-11-10 |
| ZA200605149B (en) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006907A (es) | Activador de glucocinasa. | |
| NO20060219L (no) | Forbindelser | |
| DE60336850D1 (en) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
| MX2008016423A (es) | Arilamidas sustituidas con tetrazol. | |
| EA200801381A1 (ru) | Производные пиримидина | |
| WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| GB0428514D0 (en) | Compounds | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| MX2009004096A (es) | Metabolitos de talarozol. | |
| NO20062130L (no) | 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft | |
| HRP20090195T1 (hr) | Inhibitori mitotičkih kinezina | |
| MX2009005217A (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos. | |
| NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
| DE60226469D1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren | |
| NO20071258L (no) | Imidazolforbindelser. | |
| MXPA05010521A (es) | Inhibidores de cinasa de amida de bifenilcarboxilica p38. | |
| HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| GB0308201D0 (en) | Novel compounds | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| HRP20080027T3 (hr) | 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid | |
| NO20013684L (no) | Substituerte fenetylaminderivater | |
| TW200716650A (en) | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| NO20074622L (no) | Metabolitter for NK-1 antagonister for brekninger |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |